MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Zentalis Pharmaceuticals Operating Income 2011-2026 | ZNTL
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Zentalis Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -300 M | -227 M | -217 M | -119 M | -46.8 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -46.8 M | -300 M | -182 M |
Quarterly Operating Income Zentalis Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -33.7 M | -36.1 M | -45.6 M | - | -51.4 M | -65.1 M | -24.8 M | - | -62.7 M | -104 M | -65 M | - | -54.2 M | -63.5 M | -57.9 M | -48.2 M | -62.9 M | -55.1 M | -50.3 M | -40.2 M | -34.8 M | -27.4 M | -16.4 M | -14.9 M | -12.6 M | -10.6 M | -8.72 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.72 M | -104 M | -43.6 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
-36 M | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
Arrowhead Pharmaceuticals
ARWR
|
98.3 M | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.52 | -16.3 % | $ 388 M |  Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Biogen
BIIB
|
7.04 B | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 102.17 | 2.32 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 93.52 | -1.2 % | $ 96.9 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 4.25 | 1.67 % | $ 9.25 B |  Israel |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 207.49 | 2.22 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
-69.5 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-447 M | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Zai Lab Limited
ZLAB
|
-282 M | $ 18.37 | -0.97 % | $ 18.2 B | China |
 |
Coherus BioSciences
CHRS
|
-203 M | $ 1.61 | -5.03 % | $ 152 M | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Caladrius Biosciences
CLBS
|
-22.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
-195 M | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 4.22 | -4.2 % | $ 116 M | France |
 |
Clearside Biomedical
CLSD
|
-24.8 M | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
-93.1 M | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
137 M | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
195 M | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-339 M | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-467 M | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 29.43 | 6.09 % | $ 1.43 B | USA |